Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Invanz Efficacy and Safety in Infections
NCT00398099Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2005
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of ertapenem in bacterial infection, pneumonia and urinary tract infection (UTI), sponsored by Merck & Co. Primary endpoint: Signs and symptoms of infection at 14 days. Started Jul 2005; status: completed.
02
Drugs
ertapenem
03
Conditions
bacterial infectionpneumoniaurinary tract infection (UTI)
Beyond the preview
Go deeper on NCT00398099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00398099.